ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0732

Topical Rofecoxib for OA of the Knee
Abstract Number: 0733

A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Abstract Number: 0734

Primary Total Knee Arthroplasty for Knee Osteoarthritis Among Younger versus Older Individuals: Cross-sectional Study of Surgical Appropriateness and Surgeon Decision-Making
Abstract Number: 0735

Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study
Abstract Number: 0736

Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study
Abstract Number: 0737

Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
Abstract Number: 0738

Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Abstract Number: 0739

Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Abstract Number: 0740

Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT
Abstract Number: 0741

Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Abstract Number: 0742

Googling Rheumatic Diseases: Evaluating the Reliability of Information Found on the Internet
Abstract Number: 0743

Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
Abstract Number: 0744

MDHAQ (Multidimensional Health Assessment Questionnaire) and PROMIS-29 (patient-reported Outcomes Measurement Information System) Domains for Physical Function, Pain, Fatigue, Anxiety, Depression, Sleep, and Ability to Participate Provide Virtually Identical Information
Abstract Number: 0745

Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Abstract Number: 0746

Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].